Ashe Andrew D.'s Form 4 filing
Verve Therapeutics, Inc. (VERV) · filed Dec 6, 2021
- Accession no.
- 0000899243-21-046888
- Filed
- Dec 6, 2021
- Trade date
- Dec 2, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $128.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ashe Andrew D.CIK 0001573163 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 | Common Stock | PPurchaseAcquired | +4,000 | $32.10F1 | +$128,400 | 170,722 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $31.93 to $32.12 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Chief Operating Officer